Company intelligence / Profile preview

AiTreat

Ownership: Private
Development stage: Commercial

Overview

AiTreat has developed the world's first commercial soft tissue massage treatment robot ("EMMA"), which integrates AI with robotics to deliver consistent therapeutic massage. The company has deployed units in Singapore and China commercially since at least 2019. Clinical trials are planned or ongoing in the US with Mayo Clinic collaboration as of 2024. FDA approval process underway; not yet approved for sale in the US market

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceNon-pharmacological therapyArtificial Intelligence-powered medical device
Industry: Therapeutic Medical Devices

Partnerships

Mayo Clinic (clinical trials collaboration)

Beyond the preview

Go deeper on AiTreat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AiTreat.

Explore the full profile